HKSTP
6.11.2020 13:51:12 CET | Business Wire | Press release
Hong Kong Science and Technology Parks Corporation (HKSTP) held its annual Elevator Pitch Competition 2020 (EPiC) virtually for the first time to unveil new and exciting pitching, investment and partnership opportunities as global startups face a challenging business landscape. US-based biotechnology startup, Mi Terro, topped other finalists to be crowned champion and claimed the top prize at the competition today.
HKSTP’s annual flagship event this year expanded to a week-long virtual programme. It garnered a great response with over 77,000 live views at today’s pitching competition. This year, EPiC attracted 476 entries from 37 countries and cities across five continents. A total of 170 contestants from 31 different markets entered the semi-final round, with nearly 70% of them coming from overseas.
Mi Terro, champion and winner of the Smart City category, is a company that upcycles and re-engineers protein food waste into plastic and cotton alternative fibres for the fashion, medical and packaging industries. The three Tech Category Winners, including UK-based AI & Robotics startup Arctoris, Philippines-based fintech startup PearlPay, and Portugal-based health technology startup RUBYnanomed, showcased their full potential as innovators in the competition.
Albert Wong, CEO of HKSTP, said: “This year’s successful staging of the 5th EPiC is a clear sign of our determination to provide a platform of unmatched opportunities to startups around the world to showcase their innovations and demonstrate their entrepreneurial spirit. The week-long programme is also a show of strength and resilience for Hong Kong’s rapidly-growing innovation and technology ecosystem which propels startups and their ideas to success in Hong Kong, Asia and beyond.”
Since inception in 2016, EPiC has drawn a huge number of international startups to make a live one-minute elevator pitch to leading investors and judges at the International Commerce Centre (ICC), the tallest skyscraper in Hong Kong. This year, our contestants switched modes to present their innovative business ideas, with a one-minute video pitch submitted to simulate the signature 60-second elevator ride.
The top ten finalists were given another opportunity to face the judges in a three-minute live pitch and two-minute Q&A, before announcing the overall champion, who took away a cash prize of US$100,000 while each of the category winners received a cash prize of US$10,000 and all ten finalists won US$6,000 each.
The competition marks a major progression for startups who gained valuable exposure among investors and industry leaders in their ongoing entrepreneurship journey. To further bolster the growth and development of local and overseas startups, this year’s EPiC provides a wider array of business opportunities to explore and acquire better understanding of the investment landscape in the region with the upcoming “Global Matching” programme from 9 to 12 November and the “Investment x Corporate Innovation Conference” on 13 November.
List of Winners
Award |
Company Name |
Market |
||
Champion and Tech Category Winner – Smart City |
United States |
|||
Tech Category Winner – Artificial Intelligence & Robotics |
United Kingdom |
|||
Tech Category Winner – FinTech |
Philippines |
|||
Tech Category Winner – Health Technology |
Portugal |
|||
Other Top 10 Finalists |
Australia |
|||
|
Hong Kong |
|||
|
United States |
|||
|
Hong Kong |
|||
|
Denmark |
|||
|
Hong Kong |
About Hong Kong Science and Technology Parks Corporation
Comprising Science Park, InnoCentre and Industrial Estates, Hong Kong Science & Technology Parks Corporation (HKSTP) is a statutory body dedicated to building a vibrant innovation and technology ecosystem to connect stakeholders, nurture technology talents, facilitate collaboration, and catalyse innovations to deliver social and economic benefits to Hong Kong and the region.
Established in May 2001, HKSTP has been driving the development of Hong Kong into a regional hub for innovation and growth in several focused clusters including Electronics, Information & Communications Technology, Green Technology, Biomedical Technology, Materials and Precision Engineering. We enable science and technology companies to nurture ideas, innovate and grow, supported by our R&D facilities, infrastructure, and market-led laboratories and technical centres with professional support services. We also offer value added services and comprehensive incubation programmes for technology start-ups to accelerate their growth.
Technology businesses benefit from our specialised services and infrastructure at Science Park for applied research and product development; enterprises can find creative design support at InnoCentre; while skill-intensive businesses are served by our three industrial estates at Tai Po, Tseung Kwan O and Yuen Long. More information about HKSTP is available at www.hkstp.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201106005290/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom